Predictive markers of capecitabine sensitivity identified from the expression profile of pyrimidine nucleoside-metabolizing enzymes

Oncology Reports

Volumn 29, Issue 2, 2013, Pages 451-458

  Yasuno, Hideyuki ^a   Kurasawa, Mitsue ^a   Yanagisawa, Mieko ^a   Sato, Yasuko ^a   Harada, Naoki ^a   Mori, Kazushige ^a  

^a CHUGAI PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Capecitabine; Cytidine deaminase; Dihydropyrimidine dehydrogenase; Thymidine phosphorylase; Thymidylate synthase; Uridine phosphorylase

Indexed keywords

CAPECITABINE; CYTIDINE DEAMINASE; DIHYDROPYRIMIDINE DEHYDROGENASE; DOXIFLURIDINE; FLUOROURACIL; MESSENGER RNA; MOLECULAR MARKER; OROTATE PHOSPHORIBOSYLTRANSFERASE; PROTEIN KINASE; PROTEIN TMPK; PROTEIN UMPK; PYRIMIDINE NUCLEOSIDE; RIBONUCLEOTIDE REDUCTASE; THYMIDINE KINASE 1; THYMIDINE PHOSPHORYLASE; THYMIDYLATE SYNTHASE; UNCLASSIFIED DRUG; URIDINE PHOSPHORYLASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CANCER; BREAST CANCER; CANCER INHIBITION; CHILDHOOD CANCER; CLUSTER ANALYSIS; COLORECTAL CANCER; CONTROLLED STUDY; DRUG SENSITIVITY; ENZYME ANALYSIS; HUMAN; HUMAN CELL; KIDNEY CANCER; LIVER CANCER; LUNG CANCER; MELANOMA; MOUSE; NONHUMAN; NUCLEOTIDE METABOLISM; NUCLEOTIDE SEQUENCE; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DEGRADATION; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; STOMACH CANCER; TUMOR XENOGRAFT; UTERINE CERVIX CANCER; UTERUS CANCER;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; CELL LINE, TUMOR; CYTIDINE DEAMINASE; DEOXYCYTIDINE; DIHYDROURACIL DEHYDROGENASE (NADP); FLOXURIDINE; FLUOROURACIL; MICE; MICE, NUDE; NEOPLASMS; NUCLEOSIDE-PHOSPHATE KINASE; OROTATE PHOSPHORIBOSYLTRANSFERASE; RIBONUCLEOTIDE REDUCTASES; RNA, MESSENGER; THYMIDINE KINASE; THYMIDINE PHOSPHORYLASE; THYMIDYLATE SYNTHASE; URIDINE KINASE; URIDINE PHOSPHORYLASE;

EID: 84872782137     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.2149     Document Type: Article

References (21)

1. Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K, Shimma N, Umeda I and Ishitsuka H: Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 34: 1274-1281, 1998. (Pubitemid 28342121)
2. Ishikawa T, Utoh M, Sawada N, Nishida M, Fukase Y, Sekiguchi F and Ishitsuka H: Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts. Biochem Pharmacol 55: 1091-1097, 1998. (Pubitemid 28167730)
3. Schuller J, Cassidy J, Dumont E, Roos B, Durston S, Banken L, Utoh M, Mori K, Weidekamm E and Reigner B: Preferential activation of capecitabine in tumors following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol 45: 291-297, 2000. (Pubitemid 30151522)
4. Pentheroudakis G and Twelves C: The rational development of capecitabine from the laboratory to the clinic. Anticancer Res 22: 3589-3596, 2002. (Pubitemid 36132834)
5. Ishikawa T, Sekiguchi F, Fukase Y, Sawada N and Ishitsuka H: Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts. Cancer Res 58: 685-690, 1998. (Pubitemid 28099478)
6. Aschele C, Sobrero A, Faderan MA and Bertino JR: Novel mechanism(s) of resistance to 5-fluorouracil in human colon cancer (HCT-8) sublines following exposure to two different clinically relevant dose schedules. Cancer Res 52: 1855-1864, 1992.
7. Aschele C, Lonardi S and Monfardini S: Thymidylate synthase expression as a predictor of clinical response to fluoropyrimidine-based chemotherapy in advanced colorectal cancer. Cancer Treat Rev 28: 27-47, 2002. (Pubitemid 34679207)
8. Kubota T, Watanabe M, Otani Y, Kitajima M and Fukushiuma M: Different pathways of 5-fluorouracil metabolism after continuous venous or bolus injection in patients with colon carcinoma: possible predictive value of thymidylate synthetase mRNA and ribonucleotide reductase for 5-fluorouracil sensitivity. Anticancer Res 22: 3537-3540, 2002. (Pubitemid 36132825)
9. Sawada N, Ishikawa T, Fukase Y, Nishida M, Yoshikubo T and Ishitsuka H: Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts. Clin Cancer Res 4: 1013-1019, 1998. (Pubitemid 28183404)
10. Endo M, Shinbori N, Fukase Y, Sawada N, Ishikawa T, Ishitsuka H and Tanaka Y: Induction of thymidine phosphorylase expression and enhancement of efficacy of capecitabine or 5'-deoxy-5-fluorouridine by cyclophosphamide in mammary tumor models. Int J Cancer 83: 127-134, 1999. (Pubitemid 29409488)
11. Sawada N, Ishikawa T, Sekiguchi F, Tanaka Y and Ishitsuka H: X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (Xeloda) in human cancer xenografts. Clin Cancer Res 5: 2948-2953, 1999. (Pubitemid 29493974)
12. Kurosumi M, Tabei T, Suemasu K, Inoue K, Kusawake T, Sugamata N and Higashi Y: Enhancement of immunohistochemical reactivity for thymidine phosphorylase in breast carcinoma cells after administration of docetaxel as a neoadjuvant chemotherapy in advanced breast cancer patients. Oncol Rep 7: 945-948, 2000.
13. Toi M and Ohno S: The role of thymidine phosphorylase (TP) in choosing FU/capecitabine chemotherapy. Proc Am Soc Clin Oncol 22: 137, 2003.
14. O'Shaughnessy J, Miles D, Vukelja S, Moiseyenko V, Ayoub JP, Cervantes G, Fumoleau P, Jones S, Lui WY, Mauriac L, et al: Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 20: 2812-2823, 2002. (Pubitemid 34651510)
15. Terashima M, Fujiwara H, Takagane A, Abe K, Araya M, Irinoda T, Yonezawa H, Nakaya T, Oyama K, Takahashi M, and Saito K: Role of thymidine phosphorylase and dihydropy-rimidine dehydrogenase in tumour progression and sensitivity to doxifluridine in gastric cancer patients. Eur J Cancer 38: 2375-2381, 2002. (Pubitemid 35387489)
16. Nishimura G, Terada I, Kobayashi T, Ninomiya I, Kitagawa H, Fushida S, Fujimura T, Kayahara M, Shimizu K, Ohta T and Miwa K: Thymidine phosphorylase and dihydropyrimidine dehydrogenase levels in primary colorectal cancer show a relationship to clinical effects of 5'-deoxy-5-fluorouridine as adjuvant chemotherapy. Oncol Rep 9: 479-482, 2002.
17. Ishii R, Takiguchi N, Oda K, Koda K and Miyazaki M: Thymidine phosphorylase expression is useful in selecting adjuvant chemotherapy for stage III gastric cancer. Int J Oncol 19: 717-722, 2001.
18. Nishida M, Hino A, Mori K, Matsumoto T, Yoshikubo T and Ishitsuka H: Preparation of anti-human thymidine phosphorylase monoclonal antibodies useful for detecting the enzyme levels in tumor tissues. Biol Pharm Bull 19: 1407-1411, 1996 (Pubitemid 26403242)
19. Kono T, Nishida M, Inagaki N, Tanaka Y, Yoneda M and Kasai S: Development and characterization of 1C6-203, a new monoclonal antibody specific to human thymidine phosphorylase. J Histochem Cytochem 49: 131-138, 2001.
20. Komuro Y, Watanabe T, Tsuno N, Kitayama J, Inagaki N, Nishida M and Nagawa H: The usefulness of immunohistochemical evaluation of dihydropyrimidine dehydrogenase for rectal cancer treated with preoperative radiotherapy. Hepatogastroenterology 50: 906-911, 2003. (Pubitemid 36723808)
21. Mori K, Hasegawa M, Nishida M, Toma H, Fukuda M, Kubota T, Nagasue N, Yamana H, Hirakawa-YS Chung K, Ikeda T, et al: Expression levels of thymidine phosphorylase and dihydropyrimidine dehydrogenase in various human tumor tissues. Int J Oncol 17: 33-38, 2000.